FAPi-PET Imaging of in Vivo Fibrosis in Inflammatory Bowel Disease Patients
Recruiting
Phase 2
Interventional Study
IBD (Inflammatory Bowel Disease)
Crohn Disease (CD)
Ulcerative Colitis (UC)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 20 (estimated)
- Sponsor
- Dalia Lartey · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Our main objective is to evaluate the feasibility of 68Ga-FAPi PET/CT in detecting intestinal fibrosis in patients with IBD. To this end, we will determine 68Ga-FAPi uptake in IBD in relation to cellular FAP expression in intestinal biopsies and resection specimens.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Group 1
\- Adults ≥18 years with confirmed diagnosis of Crohn's disease
AND one of the following:
* Gastrointestinal complaints such as diarrhea, bloody and/ or lose stools and abdominal pain, or obstructive symptoms.
* Increased CRP (\>5 mg/L) and/or fecal calprotectin le…
Contacts